Bryan P. Schneider
Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Bryan P. Schneider

Hematology Oncology | Oncology | Hematology
Cutting Edge Physical Therapy Limited Partnership
2390 National Rd W, 
Richmond, IN 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
Cutting Edge Physical Therapy Limited Partnership
2390 National Rd W, 
Richmond, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bryan Schneider is a Hematologist Oncology specialist and an Oncologist in Richmond, Indiana. Dr. Schneider is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Thymic Epithelial Tumor, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. Dr. Schneider is currently accepting new patients.

His clinical research consists of co-authoring 155 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health
Iu Health West Hospital
Indiana University Health North Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

CUTTING EDGE PHYSICAL THERAPY LIMITED PARTNERSHIP
2390 National Rd W, Richmond, IN 47374
Other Locations
IU HEALTH MEDICAL GROUP LLC
1701 N Senate Blvd, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Other
Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples
Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Other
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Other
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Paclitaxel
Study Phase: Phase 2
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
Enrollment Status: Terminated
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Capecitabine, Talazoparib, Atezolizumab, Inavolisib
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients With Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen
A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients With Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen
Enrollment Status: Terminated
Publish Date: August 26, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

155 Total Publications

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 10, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jill B. Cole
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jill B. Cole
Hematology Oncology | Oncology | Hematology

Major Multispecialty Associates

2455 Intelliplex Dr, 
Shelbyville, IN 
 (48.9 miles away)
317-421-1800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jill Cole is a Hematologist Oncology specialist and an Oncologist in Shelbyville, Indiana. Dr. Cole is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Cole is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David M. Waterhouse
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David M. Waterhouse
Hematology Oncology | Oncology | Hematology

Oncology Hematology Care Inc

4350 Malsbary Rd, 
Blue Ash, OH 
 (49.7 miles away)
513-891-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Waterhouse is a Hematologist Oncology specialist and an Oncologist in Blue Ash, Ohio. Dr. Waterhouse is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Waterhouse is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Benjamin T. Herms
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Benjamin T. Herms
Hematology Oncology | Hematology | Oncology

Oncology Hematology Care Inc

601 Ivy Gateway, Suite 1, 
Cincinnati, OH 
 (61.4 miles away)
513-751-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Benjamin Herms is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Herms is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Herms is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schneider's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 34 Advanced Conditions
View All 77 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile